Yazar "Uzun, Asiye" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Kapalı Erişim
    Yayın
    Association of body mass index with reproductive and metabolic outcomes in women with PCOS undergoing frozen-thawed blastocyst transfer
    (Galenos Publishing House, 2026) Aydın, Gerçek; Uzun, Asiye
    Objective: To evaluate whether body mass index (BMI) predicts in vitro fertilization (IVF) pregnancy and perinatal outcomes in women with polycystic ovary syndrome (PCOS) undergoing frozen-thawed blastocyst transfer within a standardized protocol. Material and Methods: This retrospective cohort study included 69 frozen-thawed blastocyst transfer cycles from 53 women with PCOS at a single IVF center (June 2022-June 2025). All cycles followed a uniform progestin-primed ovarian stimulation protocol with a freeze all strategy. Pregnancy outcomes were calculated per embryo transfer cycle; perinatal outcomes were assessed using a delivery-based approach. Univariable and multivariable regression analyses were performed with robust standard errors clustered by patient, with maternal age as a potential confounder. Results: The mean maternal age was 29.5±4.1 years, and the mean BMI was 25.9±6.3 kg/m2. The live birth rate per transfer was calculated as 33.3% (23/69). BMI was not significantly associated with biochemical pregnancy, clinical pregnancy, ongoing pregnancy, or live birth rates in either univariable or multivariable analyses. In univariable analysis, increasing BMI was associated with a higher risk of gestational diabetes mellitus; however, this association lost statistical significance following multivariable adjustment, though a trend in this direction could not be excluded (p=0.087). No significant association was identified between BMI and hypertensive complications of pregnancy or neonatal outcomes. Conclusion: Based on our findings, BMI does not appear to be a strong predictor of IVF pregnancy success in women with PCOS undergoing frozen-thawed blastocyst transfer. BMI may be more relevant to perinatal metabolic risk than to reproductive outcomes.
  • Küçük Resim
    Yayın
    The letrozole use in reproductive medicine: Beyond aromatase inhibition - a comprehensive review
    (Galenos Publishing House, 2026) Aydın, Gerçek; Hatırnaz, Şafak; Hatırnaz, Ebru Saynur; Çetinkaya, Mehmet Bilge; Akdeniz, Muhterem; Dokuzeylül Güngör, Nur; Güler, Oğuz; Merdanoğlu, Merdan Ali; Uzun, Asiye; Eroğlu, Semra; Dahan, Michael
    Letrozole and other aromatase inhibitors are increasingly recognized as first-line ovulation induction (OI) medications, offering an efficient and physiologic approach to ovarian stimulation that enhances outcomes in reproductive medicine. By selectively inhibiting aromatase and maintaining lower peripheral estrogen levels, letrozole supports mono- or bi-follicular development while reducing the risk of supraphysiologic estradiol exposure seen with traditional gonadotropin regimens. These pharmacological characteristics have contributed to its expanding use not only in OI but also in various assisted reproductive technologies. To evaluate the clinical benefits, effectiveness, and safety of using letrozole in in vitro fertilization (IVF), in vitro maturation (IVM), and OI, with particular attention to reproductive outcomes, ovarian response, endometrial effects, cycle characteristics, and treatment-related adverse events. A comprehensive systematic search covering the period from December 2000 to November 2025 was conducted across major electronic databases including PubMed, Embase, the Cochrane Library, and Google Scholar. The search strategy incorporated predefined keywords related to letrozole, aromatase inhibition, OI, IVF, and IVM. Studies involving randomized controlled trials, observational cohorts, and meta analyses were included, while non-clinical and non-reproductive data were excluded. Relevant outcomes were extracted and synthesized qualitatively. Letrozole demonstrates broad clinical utility in reproductive medicine, spanning assisted reproductive techniques, ovarian stimulation strategies, and the management of ovarian hyperstimulation syndrome risk, ectopic pregnancy, and endometriosis-related infertility. Its targeted estrogen suppression, cost-effectiveness, and favorable safety profile make it a valuable component of individualized treatment protocols. Nonetheless, further high-quality research is required to refine optimal dosing strategies, identify ideal patient populations, and clarify long-term reproductive and obstetric safety.